Last reviewed · How we verify
Flamboyant 200/12
Flamboyant 200/12 is a Calcium channel blocker/beta blocker combination Small molecule drug developed by EMS. It is currently in Phase 3 development for Hypertension.
Flamboyant 200/12 is a fixed-dose combination of a calcium channel blocker and a beta blocker.
Flamboyant 200/12 is a small molecule medication. It is being studied for its efficacy and safety in treating adults with moderate asthma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Flamboyant 200/12 |
|---|---|
| Sponsor | EMS |
| Drug class | Calcium channel blocker/beta blocker combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not well-documented, but it is believed to work by reducing blood pressure through a combination of vasodilation and decreased cardiac output.
Approved indications
- Hypertension
Common side effects
- Edema
- Dizziness
- Fatigue
Key clinical trials
- Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma (PHASE3)
- Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flamboyant 200/12 CI brief — competitive landscape report
- Flamboyant 200/12 updates RSS · CI watch RSS
- EMS portfolio CI
Frequently asked questions about Flamboyant 200/12
What is Flamboyant 200/12?
How does Flamboyant 200/12 work?
What is Flamboyant 200/12 used for?
Who makes Flamboyant 200/12?
What drug class is Flamboyant 200/12 in?
What development phase is Flamboyant 200/12 in?
What are the side effects of Flamboyant 200/12?
Related
- Drug class: All Calcium channel blocker/beta blocker combination drugs
- Manufacturer: EMS — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing